Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer - Concepedia

Concepedia

Publication | Open Access

Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer

DOI Full Paper Access

666

Citations

22

References

2018

Year

Jin‐Young Jang, Youngmin Han, Hongeun Lee, Sun‐Whe Kim, Wooil Kwon, Kyung-Hun Lee, Do‐Youn Oh, Eui Kyu Chie, Jeong Min Lee, Jin Seok Heo,

Annals of Surgery

Abstract

This is the first prospective randomized controlled trial on the oncological benefits of neoadjuvant treatment in BRPC. Compared to upfront surgery, neoadjuvant chemoradiation provides oncological benefits in patients with BRPC.

References

	Year	Citations

Page 1